Review
doi: 10.1016/j.amjmed.2018.05.043.
Epub 2018 Jul 2.
New Injectable Agents for the Treatment of Type 2 Diabetes Part 2-Glucagon-Like Peptide-1 (GLP-1) Agonists
Affiliations
- PMID: 29969616
- DOI: 10.1016/j.amjmed.2018.05.043
Item in Clipboard
Review
New Injectable Agents for the Treatment of Type 2 Diabetes Part 2-Glucagon-Like Peptide-1 (GLP-1) Agonists
Am J Med.
2018 Nov.
Abstract
The US Food and Drug Administration has recently approved several new glucagon-like peptide-1 (GLP-1) agonists alone and in combination with various insulin products. The second of 2 articles in a series, this review will describe the potential advantages and disadvantages of the GLP-1 agonist class of products.
Keywords: GLP-1 combination products; Glucagon like peptide-1 (GLP-1) agonist; Type 2 diabetes.
Copyright © 2018. Published by Elsevier Inc.
Similar articles
-
Glucagon like peptide-1 and its receptor agonists: Their roles in management of Type 2 diabetes mellitus.Diabetes Metab Syndr. 2017 Jul-Sep;11(3):225-230. doi: 10.1016/j.dsx.2016.09.003. Epub 2016 Sep 15. Diabetes Metab Syndr. 2017. PMID: 27884496 Review.
-
Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.Ann Pharmacother. 2012 Jan;46(1):68-78. doi: 10.1345/aph.1Q379. Ann Pharmacother. 2012. PMID: 22232377 Review.
-
Insulin and glucagon-like peptide receptor agonist (GLP 1 RA) combinations.J Pak Med Assoc. 2014 Mar;64(3):359-61. J Pak Med Assoc. 2014. PMID: 24864619 Review.
-
Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review.Expert Rev Clin Pharmacol. 2016;9(2):241-65. doi: 10.1586/17512433.2016.1121808. Epub 2016 Jan 8. Expert Rev Clin Pharmacol. 2016. PMID: 26573176 Review.
-
Cigarette smoking, type 2 diabetes mellitus, and glucagon-like peptide-1 receptor agonists as a potential treatment for smokers with diabetes: An integrative review.Diabetes Res Clin Pract. 2019 Mar;149:78-88. doi: 10.1016/j.diabres.2019.01.033. Epub 2019 Feb 5. Diabetes Res Clin Pract. 2019. PMID: 30735771 Review.
Cited by
-
Systemic elucidation on the potential bioactive compounds and hypoglycemic mechanism of Polygonum multiflorum based on network pharmacology.Chin Med. 2020 Nov 18;15(1):121. doi: 10.1186/s13020-020-00401-2. Chin Med. 2020. PMID: 33292335 Free PMC article.
-
Glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: An update.World J Hepatol. 2020 Aug 27;12(8):493-505. doi: 10.4254/wjh.v12.i8.493. World J Hepatol. 2020. PMID: 32952876 Free PMC article. Review.
-
Therapeutic peptides: current applications and future directions.Signal Transduct Target Ther. 2022 Feb 14;7(1):48. doi: 10.1038/s41392-022-00904-4. Signal Transduct Target Ther. 2022. PMID: 35165272 Free PMC article. Review.
-
Suitable Use of Injectable Agents to Overcome Hypoglycemia Risk, Barriers, and Clinical Inertia in Community-Dwelling Older Adults with Type 2 Diabetes Mellitus.Drugs Aging. 2019 Dec;36(12):1083-1096. doi: 10.1007/s40266-019-00706-4. Drugs Aging. 2019. PMID: 31565780 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
